help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology, doi:10.1210/en.2004-0089
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
145/6/2660    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Druce, M. R.
Right arrow Articles by Bloom, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Druce, M. R.
Right arrow Articles by Bloom, S. R.
Endocrinology Vol. 145, No. 6 2660-2665
Copyright © 2004 by The Endocrine Society

MINIREVIEW

Minireview: Gut Peptides Regulating Satiety

Maralyn R. Druce, Caroline J. Small and Stephen R. Bloom

Department of Metabolic Medicine, Division of Investigative Science, Imperial College London, Hammersmith Campus, London W12 ONN, United Kingdom

Address all correspondence and requests for reprints to: Stephen R. Bloom, Department of Metabolic Medicine, Division of Investigative Science, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 ONN, United Kingdom. E-mail: s.bloom{at}imperial.ac.uk.

Abstract

The gastrointestinal tract and the pancreas release hormones regulating satiety and body weight. Ghrelin stimulates appetite, and glucagon-like peptide-1, oxyntomodulin, peptide YY, cholecystokinin, and pancreatic polypeptide inhibit appetite. These gut hormones act to markedly alter food intake in humans and rodents. Obesity is the current major cause of premature death in the United Kingdom, killing almost 1000 people per week. Worldwide, its prevalence is accelerating. There is currently no effective answer to the pandemic of obesity, but replacement of the low levels of peptide YY observed in the obese may represent an effective antiobesity therapy.

OBESITY AND ITS associated complications present significant public health problems. The prevalence has increased by over 75% worldwide since 1980 (1) while in the United Kingdom, treatment of the complications associated with obesity costs the National Health Service over 0.5 billion pounds per year (2). Many advances have been made recently in the understanding of the homeostatic system that regulates body weight.

Despite the increase in population obesity, in an individual person energy balance is tightly regulated. For most people, the amount and composition of food eaten varies considerably from meal to meal and from day to day. Yet over time, energy intake is matched to expenditure, and body weight is tightly conserved. Thus, food intake, both meal frequency and meal size, must also be highly regulated.

One part of this system involves signals of body energy reserves. These include insulin and leptin, which are released into the blood in proportion to the amount of body fat and inhibit food intake. Another component of the system is the control of feeding by the gastrointestinal tract. Hunger signals trigger eating, and satiety signals inhibit appetite for a period thereafter. Together, these control frequency of eating and meal size, and hence total energy intake. The gut hormones ghrelin, peptide YY (PYY), pancreatic polypeptide (PP), oxyntomodulin (Oxm), cholecystokinin, and glucagon-like peptide-1 (GLP-1) may all play a role. The sites of production of these hormones are summarized in Fig. 1Go.



View larger version (21K):
[in this window]
[in a new window]
  		FIG. 1. Schematic summary of the central pathways involved in appetite regulation.

 
Central Pathways Involved in Appetite Regulation

Long-term and short-term hormonal signals from the periphery act on the central nervous system to influence feeding behavior. The main regions involved are the hypothalamus, in particular the arcuate nucleus, and the dorsal vagal complex in the brain stem (3, 4). The interactions between these areas are summarized in Fig. 2Go.



View larger version (31K):
[in this window]
[in a new window]
  		FIG. 2. Hormones produced by the gut. Those shown in bold are known to alter food intake and body weight.

 
The arcuate nucleus integrates signals from the periphery (it is accessible to circulating factors because the blood-brain barrier is incomplete here) and from the brain stem (5, 6). The arcuate nucleus contains two distinct subsets of neurons controlling food intake. One acts as a stimulus to feeding; these neurons contain neuropeptide Y (NPY) and agouti-related peptide. The products of these neurons stimulate food intake when injected into the central nervous system. The second subset of neurons acts as an inhibitor; these contain {alpha}-MSH and cocaine- and amphetamine-regulated transcript (CART). Direct administration of either {alpha}-MSH or CART into the central nervous system inhibits food intake. Typically, when one of these subsets is activated, the other is inhibited. The neurons are responsive to circulating hunger and satiety signals such as ghrelin, cholecystokinin, and PYY. They are also modulated by signals of long-term body energy stores such as leptin and insulin (4).

From the arcuate, neurons project to the paraventricular nucleus, the dorsomedial nucleus, and along the neuraxis from the olfactory nucleus to the nucleus tractus solitarius. The paraventricular nucleus coordinates outputs for feeding, energy metabolism, and the sympathetic nervous system and endocrine axes. It also receives inputs from the melanin-concentrating hormone projections from the lateral hypothalamus (which is a stimulator of feeding), the brain stem, and the amygdala that have an impact on food intake (7, 8).

How Your Gut Tells You It’s Time to Eat

Ghrelin
Many cues for meal initiation are learned by association. Endocrine signals are also involved. Ghrelin is a hormone synthesized in the stomach (9), and both the expression and circulating levels are up-regulated by fasting (10, 11). Ghrelin is the endogenous ligand for the GH secretagogue receptor (12, 13), which is expressed in hypothalamic and brain stem nuclei including the arcuate nucleus (14). The structure of ghrelin is highly conserved across species, suggesting an important physiological role.

In rodents, ghrelin is a potent stimulus to feeding, with a maximum effect observed within 1 h of peripheral administration (11, 15). The resultant plasma levels are comparable to those observed after a 24-h fast (11). Ghrelin levels are influenced by gut nutrients rather than gastric distension, with fasting ghrelin levels being suppressed by an oral glucose load but not altered by the same volume of water (16). Chronic ghrelin administration induces adiposity (11, 16) without attenuation of the effects on food intake (11, 15). Ghrelin also has local gut effects in addition to its effects on appetite, stimulating gastric emptying and decreasing gastric acid secretion in rodents (17). It has also been reported to reverse the temporary paralysis of the gut (ileus) observed after abdominal surgery (18).

Human data also support a role for ghrelin in appetite regulation (19). As in rodents, ghrelin is principally secreted by the stomach, with levels in gastrectomy patients around 35% of those of age-matched controls (20). Plasma levels are high in the fasted state and fall after eating (21). Exogenous infusion of ghrelin increases food intake at a buffet meal by 28% in human subjects, compared with a saline control day (19). Despite the increased food intake, there is no difference in satiety after the meal, and total food intake on the ghrelin day is more than on the control day (19).

A role for ghrelin in the etiology of human obesity has been proposed. Ghrelin has an inverse relationship with body mass index and is significantly lower in obese subjects compared with lean (22). Ghrelin is the "hormone of hunger," and this picture would fit with the notion of homeostatic control of body weight; high circulating ghrelin in thin individuals would favor increased food intake and positive energy balance. Weight loss in obese people results in an elevation in ghrelin level (23), which may contribute to the difficulty seen in maintaining body weight after weight loss. Food fails to suppress ghrelin levels in obese humans (24), which again could impair postprandial satiety and contribute to overeating. Indeed, individuals with Prader Willi syndrome have grossly elevated ghrelin levels, and this could be a cause of the hyperphagia (25). Mutations in the ghrelin gene have been identified in man, but a role for these in weight determination remains controversial (26, 27, 28).

How Your Gut Tells You You’ve Eaten Enough

PYY
PYY is a peptide belonging to the NPY family. It is produced by the gut and is released into the circulation after meals (29, 30). The main form of PYY both stored and in circulation is PYY 3-36 (31), and this is an N-terminally truncated form of the full-length peptide.

Peripheral administration of PYY was first reported in 1993 to decrease appetite (32). In addition, when PYY 3-36 is administered peripherally to mouse, rat, or human, there is marked inhibition of food intake (30, 33). The pattern of c-fos expression in the brain after peripheral administration of PYY 3-36 shows a marked induction of c-fos in the arcuate nucleus. Injection of PYY 3-36 directly into the arcuate nucleus inhibits food intake, and chronic administration of PYY 3-36 leads to a decrease in food intake and body weight. Addition of PYY 3-36 to ex vivo hypothalamic explants inhibits release of NPY and stimulates release of {alpha}-MSH. Peripheral administration of PYY 3-36 in rats causes a decrease in expression of arcuate NPY mRNA. PYY 3-36 has a high affinity for the Y2 receptor (Y2R), a member of the NPY family of G protein-coupled receptors. Inhibition of appetite is also seen with a Y2R-specific agonist and is absent in the Y2R knockout mouse (30, 33). It appears that circulating PYY 3-36 inhibits appetite by acting directly on the arcuate nucleus via the Y2R, a presynaptic inhibitory auto receptor (30, 33).

In humans, food intake in a free-choice meal is reduced by 30% after an iv infusion of PYY 3-36, which results in plasma levels similar to those achieved physiologically after a meal (30, 33). Obese subjects have lower basal fasting PYY 3-36 levels and a smaller rise in postprandial levels (34). Obesity does not appear to be associated with resistance to PYY (as it is with leptin), and exogenous infusion of PYY 3-36 results in a reduction in food intake by 30% in an obese group and 31% in a lean group (34).

After a meal, PYY is released shortly after food intake; this is likely to be under neural control because it occurs before ingested nutrients reach the distal small intestine and colon, where the greatest concentrations of PYY 3-36 are found (29, 35). Further release is seen when the nutrients arrive at this region of gut and is particularly stimulated by carbohydrates and lipids. PYY is likely to affect appetite via a direct central effect and also via its effects on gut motility; it acts as an "ileal brake" and so leads to a sensation of fullness and satiety (30, 33).

PP
PP is a 36-amino acid peptide from the NPY family. It is produced in the pancreatic islets (36). The amount of PP release is dependent on the digestive state: release is low when fasted and increased throughout all phases of digestion (37, 38, 39).

Evidence from rodents for a role for PP in appetite control includes the finding that chronic ip administration of PP to genetically obese mice reduces food intake and weight gain (40). Mice that overexpress PP have reduced food intake and body mass (41). PP reduces food intake in both obese and lean mice, with the obese mice being less sensitive to its effects (42), but this finding is not always replicated (43). Whether these findings mirror a physiological role is unclear.

In humans, obese individuals with Prader-Willi syndrome have low basal and meal-stimulated levels of PP, and exogenous administration of iv PP reduces food intake (44). PP administration to normal-weight individuals reduces food intake by a mean of 21.8% at a free-choice buffet meal, and this reduction in intake was maintained until the morning after the infusion (37).

Oxm
Oxm is produced by processing of preproglucagon in the gut and brain and is released after eating (45, 46, 47, 48). Central administration of Oxm inhibits food intake in the rat with greater potency than does GLP-1 (49). Oxm appears to act via a GLP-1-like receptor because its anorectic actions are blocked by coadministration of the GLP-1 receptor antagonist, exendin 9-39 (49).

Recently, it was shown that Oxm is also a potent inhibitor of food intake when administered ip to rats (49A ). Intraperitoneal administration of Oxm results in c-fos expression in the arcuate nucleus, a region partially outside the blood-brain barrier, but there is little activation of neurons in the nucleus of the solitary tract in the brain stem. These experiments demonstrate that Oxm has a very different pattern of neuronal activation from that of GLP-1. When the antagonist exendin 9-39 is injected into the arcuate nucleus, circulating Oxm no longer inhibits food intake, suggesting an arcuate site of action. By contrast, the effect of circulating GLP-1, acting via the brain stem, is unaffected.

In humans, iv infusion of Oxm reduces food intake at a free-choice buffet meal by 19.3%, with the total calorie intake remaining lower at 12 h after infusion (50). Further work is needed to establish a role physiologically for reduction in appetite after a meal and for homeostatic regulation of body weight.

GLP-1
Like Oxm, GLP-1 is produced by processing of the proglucagon gene in the gut and the brain, and GLP-1 (7-36) amide is the active truncated form of this peptide (45, 46, 47, 48). Feeding releases GLP-1 from the gut and into the circulation. GLP-1 acts on the pancreas to cause insulin release (51, 52, 53) but also has effects on appetite (Ref. 54 ; for extensive review, see Ref. 55).

In rodents, peripheral administration inhibits food intake, and the expression of the early gene c-fos is increased in the brain stem (56). This contrasts with the probable arcuate site of action of Oxm. Central administration also inhibits food intake, and the specific GLP-1 receptor antagonist exendin 9-39 leads to increased food intake (54).

The role for GLP-1 in physiological control of human appetite is not clear. Peripheral administration does inhibit food intake in normal individuals (57), in diabetics (58, 59), and in nondiabetic obese men (60). However, when infusions achieve levels comparable to those seen in the physiological state after meals, the effect on appetite and food intake is small (61, 62).

Some reports have suggested that GLP-1 secretion is reduced in obese subjects, and weight loss normalizes the levels (61). However, other findings do not support these observations (63, 64, 65, 66). The anorectic effects of GLP-1 are, however, preserved in obesity. Prandial sc GLP-1 given for 5 d to obese, but otherwise healthy, human subjects results in a reduction of calorie intake of 15% and weight loss of 0.5 kg (67). A reduced secretion of GLP-1 could therefore contribute to the pathogenesis of obesity, and agonists of the GLP-1 receptor are potential targets for treatment. The therapeutic potential of GLP-1 is limited by its rapid breakdown. GLP-1 is deactivated by dipeptidyl peptidase IV, which cleaves off the two N-terminal amino acid residues. Recent trials have shown that inhibition of dipeptidyl peptidase IV may be an effective treatment for type II diabetes mellitus (68) but does not affect weight. Various resistant analogs in development such as exendin 4 (69) (exenatide, Amylin Pharmaceuticals, Inc., San Diego, CA) and albumin-based forms such as Liraglutide (70, 71) (Novo Nordisk, Bagsvaerd, Denmark) may improve glycemic control and reduce body weight.

Signals of Long-Term Energy Stores

The adipocyte hormone leptin was first discovered in 1994 (72). It circulates at concentrations proportional to body fat mass and inhibits food intake (73). It acts on the arcuate nucleus to stimulate the anorexigenic neurons and inhibit the orexigenic population (74) and modulates the effects of the shorter-term circulating signals. It plays an important part in the homeostatic control of body-fat mass and in particular in the response to fasting (75). In addition, some leptin has now been shown to be secreted by the gastrointestinal tract and, contentiously, may also function as a gut hormone (76, 77). Insulin also circulates at levels proportional to fat mass and is also likely to function as another adiposity signal (78). The levels of the long-term signals of body adiposity, e.g. leptin and the postprandial levels of gut hormones, e.g. ghrelin and PYY, influence the activity of the NPY/agouti-related peptide and proopiomelanocortin/CART neurons in the arcuate nucleus. The activity of these two neuronal populations increases or decreases the drive to eat and integrates both the long-term and short-term circulating signals of nutritional status.

Clinical Applications

Evidence suggests that the gut acts as a nutriment sensor, resulting in the release of several hormones. These signal hunger or satiety, and these messages integrate with signals of long-term energy stores to control feeding behavior. Thus, energy intake and hence body weight are tightly regulated.

The homeostatic control of body weight makes obesity an intractable problem for the individual. Several approaches are currently used to treat obesity, but all have associated problems, and many, in particular pharmacological agents such as orlistat and sibutramine, have limited effectiveness (79, 80). In contrast, gastric and intestinal bypass surgery can result in lasting weight loss (81). After such surgery, malabsorption, if it occurs, is temporary, yet the appetite effects may last many years, and this may be due to the alterations in hormonal milieu with changes in several of the signals known to affect appetite. For example, ghrelin is reduced, and the usual peaks before meals are no longer seen (21, 82), whereas PYY is increased (83).

Alteration of the levels of hormones controlling appetite by means other than surgery may thus prove equally successful at reducing food intake and body weight. Evidence from humans at present mostly has used single iv infusions. This method would clearly be impractical for long-term therapy, but results after chronic administration by other means such as sc injections, pumps, and other routes are awaited.

Footnotes

Abbreviations: CART, Cocaine- and amphetamine-regulated transcript; GLP-1, glucagon-like peptide-1; NPY, neuropeptide Y; Oxm, oxyntomodulin; PP, pancreatic polypeptide; PYY, peptide YY; Y2R, Y2 receptor.

Received January 26, 2004.

Accepted for publication March 8, 2004.

References

  1. Flegal KM, Carroll MD, Ogden CL, Johnson CL 2002 Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288:1723–1727[Abstract/Free Full Text]
  2. Bourne J 2001 Tackling obesity in England. 1–72. 7–2-2001. London: National Audit Office
  3. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS 1999 Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 20:68–100[Abstract/Free Full Text]
  4. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG 2000 Central nervous system control of food intake. Nature 404:661–671[Medline]
  5. Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ 2001 The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 25(Suppl 5):S63–S67
  6. Cowley MA, Cone RD, Enriori P, Louiselle I, Williams SM, Evans AE 2003 Electrophysiological actions of peripheral hormones on melanocortin neurons. Ann NY Acad Sci 994:175–186[Abstract/Free Full Text]
  7. Williams G, Bing C, Cai XJ, Harrold JA, King PJ, Liu XH 2001 The hypothalamus and the control of energy homeostasis. Different circuits, different purposes. Physiol Behav 74:683–701[CrossRef][Medline]
  8. Broberger C, Hokfelt T 2001 Hypothalamic and vagal neuropeptide circuitries regulating food intake. Physiol Behav 74:669–682[CrossRef][Medline]
  9. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K 1999 Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660[CrossRef][Medline]
  10. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA, Kasuga M 2001 Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120:337–345[CrossRef][Medline]
  11. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, Batterham RL, Taheri S, Stanley SA, Ghatei MA, Bloom SR 2001 Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540–2547[Abstract/Free Full Text]
  12. Bednarek MA, Feighner SD, Pong SS, Mckee KK, Hreniuk DL, Silva MV, Warren VA, Howard AD, Van der Ploeg LH, Heck JV 2000 Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem 43:4370–4376[CrossRef][Medline]
  13. Kojima M, Hosoda H, Matsuo H, Kangawa K 2001 Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 12:118–122[CrossRef][Medline]
  14. Guan XM, Yu H, Palyha OC, Mckee KK, Feighner SD, Sirinathsinghji DJ, Smith RG, Van der Ploeg LH, Howard AD 1997 Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 48:23–29[Medline]
  15. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, Bloom SR 2000 The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141:4325–4328[Abstract/Free Full Text]
  16. Tschop M, Smiley DL, Heiman ML 2000 Ghrelin induces adiposity in rodents. Nature 407:908–913[CrossRef][Medline]
  17. Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M, Kangawa K 2000 Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 276:905–908[CrossRef][Medline]
  18. Trudel L, Tomasetto C, Rio MC, Bouin M, Plourde V, Eberling P, Poitras P 2002 Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am J Physiol Gastrointest Liver Physiol 282:G948–G952
  19. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR 2001 Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992[Abstract/Free Full Text]
  20. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Toyooka S, Shirakami G, Usui T, Shimatsu A, Doi K, Hosoda H, Kojima M, Kangawa K, Nakao K 2001 Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86:4753–4758[Abstract/Free Full Text]
  21. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ 2002 Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623–1630[Abstract/Free Full Text]
  22. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S 2002 Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87:240–244[Abstract/Free Full Text]
  23. Hansen TK, Dall R, Hosoda H, Kojima M, Kangawa K, Christiansen JS, Jorgensen JO 2002 Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) 56:203–206[CrossRef][Medline]
  24. English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP 2002 Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 87:2984[Abstract/Free Full Text]
  25. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, Basdevant A, Weigle DS 2002 Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 8:643–644[CrossRef][Medline]
  26. Wang HJ, Geller F, Dempfle A, Schauble N, Friedel S, Lichtner P, Fontenla-Horro F, Wudy S, Hagemann S, Gortner L, Huse K, Remschmidt H, Bettecken T, Meitinger T, Schafer H, Hebebrand J, Hinney A 2004 Ghrelin receptor gene: identification of several sequence variants in extremely obese children and adolescents, healthy normal-weight and underweight students, and children with short normal stature. J Clin Endocrinol Metab 89:157–162[Abstract/Free Full Text]
  27. Hinney A, Hoch A, Geller F, Schafer H, Siegfried W, Goldschmidt H, Remschmidt H, Hebebrand J 2002 Ghrelin gene: identification of missense variants and a frameshift mutation in extremely obese children and adolescents and healthy normal weight students. J Clin Endocrinol Metab 87:2716[Abstract/Free Full Text]
  28. Korbonits M, Gueorguiev M, O’Grady E, Lecoeur C, Swan DC, Mein CA, Weill J, Grossman AB, Froguel P 2002 A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children. J Clin Endocrinol Metab 87:4005–4008[Abstract/Free Full Text]
  29. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR 1985 Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070–1077[Medline]
  30. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR 2002 Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650–654[CrossRef][Medline]
  31. Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, Reeve Jr JR 1994 Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51:151–159[CrossRef][Medline]
  32. Okada S, Ohshima K, Mori M, Tatemoto K Peripheral not central administered PYY decreases high fat diet intake. Program of the 75th Annual Meeting of The Endocrine Society, Las Vegas, NV, 1993, Abstract 180
  33. Batterham RL, Bloom SR 2003 The gut hormone peptide YY regulates appetite. Ann NY Acad Sci 994:162–168[Abstract/Free Full Text]
  34. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR 2003 Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349:941–948[Abstract/Free Full Text]
  35. Onaga T, Zabielski R, Kato S 2002 Multiple regulation of peptide YY secretion in the digestive tract. Peptides 23:279–290[CrossRef][Medline]
  36. Katsuura G, Asakawa A, Inui A 2002 Roles of pancreatic polypeptide in regulation of food intake. Peptides 23:323–329[CrossRef][Medline]
  37. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA, Bloom SR 2003 Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88:3989–3992
  38. Adrian TE, Besterman HS, Cooke TJ, Bloom SR, Barnes AJ, Russell RC 1977 Mechanism of pancreatic polypeptide release in man. Lancet 1:161–163[Medline]
  39. Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz PH, Barnes AJ 1976 Distribution and release of human pancreatic polypeptide. Gut 17:940–944[Abstract/Free Full Text]
  40. Malaisse-Lagae F, Carpentier JL, Patel YC, Malaisse WJ, Orci L 1977 Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse. Hypothesis. Experientia 33:915–917[CrossRef][Medline]
  41. Ueno N, Inui A, Iwamoto M, Kaga T, Asakawa A, Okita M, Fujimiya M, Nakajima Y, Ohmoto Y, Ohnaka M, Nakaya Y, Miyazaki JI, Kasuga M 1999 Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 117:1427–1432[CrossRef][Medline]
  42. McLaughlin CL, Baile CA 1981 Obese mice and the satiety effects of cholecystokinin, bombesin and pancreatic polypeptide. Physiol Behav 26:433–437[CrossRef][Medline]
  43. Taylor IL, Garcia R 1985 Effects of pancreatic polypeptide, caerulein, and bombesin on satiety in obese mice. Am J Physiol 248:G277–G280
  44. Berntson GG, Zipf WB, O’Dorisio TM, Hoffman JA, Chance RE 1993 Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides 14:497–503[CrossRef][Medline]
  45. Holst JJ 1997 Enteroglucagon. Annu Rev Physiol 59:257–271[CrossRef][Medline]
  46. Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG, Bloom SR 1983 Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 57:488–495[Abstract]
  47. Bloom SR, Polak JM 1980 Gut hormones. Adv Clin Chem 21:177–244[Medline]
  48. Bloom SR, Polak JM 1978 The new peptide hormones of the gut and their clinical significance. Acta Gastroenterol Belg 41:371–393[Medline]
  49. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, Bloom SR 2001 Oxyntomodulin inhibits food intake in the rat. Endocrinology 142:4244–4250[Abstract/Free Full Text]
  50. Dakin C, Small C, Batterham R, Neary N, Cohen M, Patterson M, Ghatei M, Bloom S 4 March 2004 Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 10.1210/en.2003-1338
  51. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR 2003 Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88:4696–4701[Abstract/Free Full Text]
  52. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR 1999 Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48:86–93[Abstract]
  53. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR 1995 Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95:417–421
  54. Kreymann B, Williams G, Ghatei MA, Bloom SR 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300–1304[Medline]
  55. Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR 1996 A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69–72[CrossRef][Medline]
  56. Vilsboll T, Holst JJ 2004 Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47:357–366[CrossRef][Medline]
  57. Tang-Christensen M, Vrang N, Larsen PJ 2001 Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord 25(Suppl 5):S42–S47
  58. Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C 1999 Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44:81–86[Abstract/Free Full Text]
  59. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C 1999 Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541–R1544
  60. Toft-Nielsen MB, Madsbad S, Holst JJ 1999 Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137–1143[Abstract/Free Full Text]
  61. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, Hellstrom PM 1999 Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23:304–311[CrossRef][Medline]
  62. Verdich C, Toubro S, Buemann B, Lysgard MJ, Juul HJ, Astrup A 2001 The role of postprandial releases of insulin and incretin hormones in meal-induced satiety—effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25:1206–1214[CrossRef][Medline]
  63. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A 2001 The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25:781–792[Medline]
  64. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, Holst JJ 2003 Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88:2706–2713[Abstract/Free Full Text]
  65. Vilsboll T, Agerso H, Krarup T, Holst JJ 2003 Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224[Abstract/Free Full Text]
  66. Velasquez-Mieyer PA, Cowan PA, Umpierrez GE, Lustig RH, Cashion AK, Burghen GA 2003 Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects. Int J Obes Relat Metab Disord 27:1359–1364[CrossRef][Medline]
  67. Feinle C, Chapman IM, Wishart J, Horowitz M 2002 Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 23:1491–1495[CrossRef][Medline]
  68. Naslund E 2004 Prandial subcutaneous injections of GLP-1 cause weight loss in obese human subjects. Br J Nutr 91:439–446[CrossRef][Medline]
  69. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA 2002 Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440:269–279[CrossRef][Medline]
  70. Egan JM, Meneilly GS, Elahi D 2003 Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 284:E1072–E1079
  71. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB 2003 The GLP-1 derivative NN2211 restores ß-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52:1786–1791[Abstract/Free Full Text]
  72. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Porksen N, Schmitz O 2002 Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51:424–429[Abstract/Free Full Text]
  73. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM 1994 Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432[CrossRef][Medline]
  74. Friedman JM, Halaas JL 1998 Leptin and the regulation of body weight in mammals. Nature 395:763–770[CrossRef][Medline]
  75. Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, Horvath TL, Cone RD, Low MJ 2001 Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 411:480–484[CrossRef][Medline]
  76. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos FE, Flier JS 1996 Role of leptin in the neuroendocrine response to fasting. Nature 382:250–252[CrossRef][Medline]
  77. Bado A, Levasseur S, Attoub S, Kermorgant S, Laigneau JP, Bortoluzzi MN, Moizo L, Lehy T, Guerre-Millo M, Marchand-Brustel Y, Lewin MJ 1998 The stomach is a source of leptin. Nature 394:790–793[CrossRef][Medline]
  78. Mix H, Widjaja A, Jandl O, Cornberg M, Kaul A, Goke M, Beil W, Kuske M, Brabant G, Manns MP, Wagner S 2000 Expression of leptin and leptin receptor isoforms in the human stomach. Gut 47:481–486[Abstract/Free Full Text]
  79. Woods SC, Porte Jr D 1983 The role of insulin as a satiety factor in the central nervous system. Adv Metab Disord 10:457–468[Medline]
  80. Finer N 2002 Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord 26(Suppl 4):S29–S33
  81. Finer N 2002 Pharmacotherapy of obesity. Best Pract Res Clin Endocrinol Metab 16:717–742[CrossRef][Medline]
  82. Mitchell JE, Lancaster KL, Burgard MA, Howell LM, Krahn DD, Crosby RD, Wonderlich SA, Gosnell BA 2001 Long-term follow-up of patients’ status after gastric bypass. Obes Surg 11:464–468[CrossRef][Medline]
  83. Cummings DE, Shannon MH 2003 Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab 88:2999–3002[Free Full Text]
  84. Naslund E, Gryback P, Hellstrom PM, Jacobsson H, Holst JJ, Theodorsson E, Backman L 1997 Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21:387–392[CrossRef][Medline]



This article has been cited by other articles:


Home page
 RadiologyHome page
A. Arepally, B. P. Barnett, E. Montgomery, and T. H. Patel
Catheter-directed Gastric Artery Chemical Embolization for Modulation of Systemic Ghrelin Levels in a Porcine Model: Initial Experience
Radiology, July 1, 2007; 244(1): 138 - 143.
[Abstract] [Full Text] [PDF]

Home page
 J DAIRY SCIHome page
A. E. Relling and C. K. Reynolds
Plasma Concentrations of Gut Peptides in Dairy Cattle Increase after Calving
J Dairy Sci, January 1, 2007; 90(1): 325 - 330.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Iqbal, Y. Kurose, B. Canny, and I. J. Clarke
Effects of Central Infusion of Ghrelin on Food Intake and Plasma Levels of Growth Hormone, Luteinizing Hormone, Prolactin, and Cortisol Secretion in Sheep
Endocrinology, January 1, 2006; 147(1): 510 - 519.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. A. Shea, M. F. Hilton, C. Orlova, R. T. Ayers, and C. S. Mantzoros
Independent Circadian and Sleep/Wake Regulation of Adipokines and Glucose in Humans
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2537 - 2544.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
L. M. Hunt, E. W. Hogeland, M. K. Henry, and S. J. Swoap
Hypotension and bradycardia during caloric restriction in mice are independent of salt balance and do not require ANP receptor
Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1446 - H1451.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Ahima and S. Y. Osei
Leptin and Appetite Control in Lipodystrophy
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4254 - 4257.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
145/6/2660    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Druce, M. R.
Right arrow Articles by Bloom, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Druce, M. R.
Right arrow Articles by Bloom, S. R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals